Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) It wasn't that long ago that obesity drugs were considered a lifestyle drug.

Is Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) an exceptional investment now? Prominent investors are taking a bullish view.

Bullish bets were unusually popular on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) yesterday, with call volume on the drug stock rising to more than three times the expected level.

Editor's Note: Related tickers: Exxon Mobil Corporation (NYSE:XOM), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), 3M Co (NYSE:MMM), Akamai Technologies, Inc. (NASDAQ:AKAM), QUALCOMM, Inc. (NASDAQ:QCOM), VIVUS, Inc. (NASDAQ:VVUS), ...

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) A sharp drop in Arena Pharmaceuticals (NASDAQ:ARNA) followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application (�MAA�) in the EU.

Investors Alert: Arena Pharmaceuticals, Inc.(NASDAQ:ARNA), Mechel OAO, Michael Kors Holdings Ltd, DeVry Inc. (NYSE:DV) (SBWire) ThePennyStockProfiler, an investment community with a special focus on updating investors with recent news on the U.S.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traded down 9.16% on last day of the week, and closed at $7.63. The stock traded in the band of $7.50 and $7.81 and the range for the 52-week is $2.52 and $13.50.

SAN DIEGO, May 10, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that the company is scheduled to present a corporate overview at the Bank of America Merrill Lynch 2013 Health Care Conference on Wednesday, ...

SAN DIEGO, April 26, 2013 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that it will provide a corporate update and discuss first quarter 2013 financial results after the NASDAQ Global Select Market closes on Thursday, ...

Yesterday, when it announced its results, Arena Pharmaceuticals, Inc.(NASDAQ:ARNA) had said that it was withdrawing its application for approval of its weight loss drug Belviq in Europe.